Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.36 |
| ▸ | ARNT | P27540 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804997 | 1.00 | TSHR (0.54) | TSHRTDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL16174900 | 0.83 | ALDH1A1 (0.48) | TSHRTDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL11303709 | 0.83 | ALDH1A1 (0.48) | TSHRTDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL10980919 | 0.82 | TSHR (0.62) | TSHRTDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL23227883 | 0.80 | ALDH1A1 (0.45) | TSHRTDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL102206 | 0.80 | TSHR (0.45) | TSHRTDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL30297073 | 0.80 | PTGER4 (0.48) | TSHRTDP1ALDH1A1MAPK1GRIN2D | |
| SCHEMBL23178591 | 0.80 | ALDH1A1 (0.45) | TSHRTDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL20797684 | 0.80 | PTGER4 (0.48) | TSHRTDP1ALDH1A1MAPK1GRIN2D | |
| SCHEMBL27843142 | 0.80 | TSHR (0.45) | TSHRTDP1ALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130900-A1 | Controlled Release Pharmaceutical Composition | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2026-05-14 | — | — | US | disclosed |
| EP-4616850-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-09-17 | — | — | EP | disclosed |
| US-20250066319-A1 | NOVEL ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R, 3S)-2-(3-(4,5-DICHLORO-1H-BENZO[d]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-02-27 | — | — | US | disclosed |
| US-20250051302-A1 | Method for Preparation of (2R,3S)-2-(benzo[d]imidazolylpropyl)piperidin-3-ol Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-02-13 | — | — | US | disclosed |
| WO-2024101937-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | 주식회사 대웅제약 | 2024-05-16 | — | — | WO | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| WO-2023113540-A1 | NOVEL ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R,3S)-2-(3-(4,5-DICHLORO-1H-BENZO[D]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL | 주식회사 대웅제약 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023113534-A1 | METHOD FOR PREPARATION OF (2R, 3S)-2-(BENZO[D]IMIDAZOLYLPROPYL)PIPERIDIN-3-OL DERIVATIVES | 주식회사 대웅제약 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023113534-A1 | METHOD FOR PREPARATION OF (2R, 3S)-2-(BENZO[D]IMIDAZOLYLPROPYL)PIPERIDIN-3-OL DERIVATIVES | 주식회사 대웅제약 | 2023-06-22 | — | — | WO | disclosed |
| CN-114728917-A | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021110076-A1 | OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 深圳信立泰药业股份有限公司 | 2021-06-10 | — | — | WO | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100201-A1 | Inhibitors of c-fms kinase | MUSK, FLT3, FES | TSHR 961/4885TDP1 2371/4885ALDH1A1 4796/4885 |
| US-20250066319-A1 | NOVEL ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R, 3S)-2-(3-(4,5-DICHLORO-1H-BENZO[d]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL | PKD2, PKD1, SLC16A8 | TSHR 3776/4885TDP1 3153/4885ALDH1A1 660/4885 |
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | TSHR 4560/4885TDP1 7/4885ALDH1A1 4135/4885 |
| US-20250051302-A1 | Method for Preparation of (2R,3S)-2-(benzo[d]imidazolylpropyl)piperidin-3-ol Derivatives | PIR, CBR3, UBE2D3 | TSHR 3404/4885TDP1 4292/4885ALDH1A1 721/4885 |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | TSHR 1802/4885TDP1 2818/4885ALDH1A1 707/4885 |
| US-20260130900-A1 | Controlled Release Pharmaceutical Composition | AARS1, RRS1, MARS1 | TSHR 1405/4885TDP1 578/4885ALDH1A1 2977/4885 |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | TSHR 1348/4885TDP1 317/4885ALDH1A1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.